A new CAR T cell therapy targeting ovarian cancer
Official title: An allogeneic gamma/delta armored Dual-Targeting CAR with Split Costimulatory Domains to Target Epithelial Ovarian Carcinoma
Funded at Luminary Therapeutics, INC. · NIH-10921643 · Data updated 2026-11-12
This study is testing a new type of CAR T cell therapy for women with ovarian cancer that uses special immune cells to better target the cancer and includes a safety feature to help protect patients from side effects.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Luminary Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | September 13, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $399,256 |
| NIH project number | 1R43CA291415-01 |
| Project ID | NIH-10921643 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with epithelial ovarian carcinoma who have not responded to standard treatments.
✕Less likely to help
Patients with hematological malignancies or those not diagnosed with solid tumors may not benefit from this research.
What this research studies
This research focuses on developing a novel CAR T cell therapy specifically designed to treat epithelial ovarian carcinoma. It utilizes an allogeneic gamma/delta T cell platform combined with a split CAR approach, which targets two different antigens to minimize the risk of antigen escape. The therapy also includes an inducible suicide switch to enhance patient safety and reduce side effects. By addressing the challenges of solid tumors, this innovative treatment aims to improve T cell persistence and effectiveness in combating cancer.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer treatment option for patients with epithelial ovarian carcinoma.
How similar studies have gone: While CAR T cell therapies have shown success in hematological cancers, this approach for solid tumors is relatively novel and has not been extensively tested.
Where this research is happening
-
Luminary Therapeutics, INC.
Minneapolis, United States Active
Researchers
- Principal investigator: Hickenlooper, Samuel — Luminary Therapeutics, INC.
- Study coordinator: Hickenlooper, Samuel
Related research
Other NIH-funded projects on the same topics.
-
Using imaging data to predict outcomes in ovarian cancer patients
This study is looking at how regular CT scans can be used to find important clues that help predict how well women with a specific type of ovarian cancer might do after treatment, so doctors can make better choices for their care.
-
Hippo/YAP pathway in aggressive ovarian cancer
Researchers aim to find out how a cell-control system called Hippo/YAP helps start and drive the most deadly form of ovarian cancer in women.
-
Blocking CDK7 as a new approach for aggressive ovarian cancer
This work explores whether blocking a protein called CDK7 can help treat women with high-grade serous ovarian cancer, especially tumors with CDK7 loss or BRCA-related DNA repair problems.
-
New methods to treat a specific type of ovarian cancer
This study is looking at a tough type of ovarian cancer called high-grade serous tubo-ovarian carcinoma to find out why it often doesn't respond to regular treatments, and it's testing new therapy combinations to help improve outcomes for patients like you.
-
Combining trametinib and navitoclax to treat recurrent ovarian cancer
This study is testing a new combination treatment for women with recurrent ovarian cancer that hasn't responded to standard therapies, aiming to see if it can help improve their outcomes.
-
Targeting a specific protein to treat advanced ovarian cancer
This study is looking at a new way to help people with advanced ovarian cancer by targeting a specific protein that helps cancer cells survive, hoping to make current treatments work better for those who have few options left.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.